GlobeNewswire Inc.··Castle Biosciences, Inc.Castle Biosciences' Melanoma Test Validates Risk Stratification in Landmark 912-Patient Study
Castle Biosciences' DecisionDx-Melanoma test confirmed 2.6% nodal positivity in 912 patients predicted low-risk, supporting safe SLNB avoidance and validating the diagnostic platform.
CSTLgene expression profileprecision oncology